Prestige Consumer Healthcare (PBH) AI Stock Analysis

• Market Cap: $3.26B
• Dividend Yield: N/A
• Average Volume (3M): 456.76K
• Price to Earnings (P/E): 15.8
• Beta (1Y): 0.29
• Revenue Growth: -0.02%
• EPS Growth: -1.87%
• Country: US
• Employees: 600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 1.14
• Shares Outstanding: 47,318,730
• 10 Day Avg. Volume: 504,397
• 30 Day Avg. Volume: 456,760
• PEG Ratio: 7.62
• Price to Book (P/B): 2.33
• Price to Sales (P/S): 3.76
• P/FCF Ratio: 17.56
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 3.88
• Enterprise Value/Gross Profit: 6.88
• Enterprise Value/Ebitda: 12.65
• 1Y Price Target: $76.00
• Price Target Upside: 10.03% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 4.54
• Revenue Forecast (FY): $1.10B

• Rating: 73 Outperform
• Price Target: $73.00 ▲(5.69% Upside)
• Action: Upgraded Date: 02/06/26
• Date: Action: Upgraded 02/06/26

PBH scores well on financial performance driven by strong cash flow and healthy margins, supported by constructive (but not fully recovered) technical momentum. The earnings call reinforces cash-flow durability and margin improvement, but the overall score is held back by ongoing revenue softness tied to supply constraints and a mid-range valuation with no dividend yield provided.

Positive Factors

Strong free cash flow generation

Consistent, high operating cash flow and near-par free-cash-flow conversion support durable internal funding for brand investment, CAPEX, M&A and buybacks. This cash resilience reduces refinancing risk and gives management optionality through economic cycles.

High and sustainable margins

Elevated gross and operating margins reflect branded OTC pricing power and a portfolio of high-margin products. Margin strength cushions profit impact from revenue softness, enabling continued investment in marketing and supply rebuilds while preserving cash generation.

Improved leverage and balance sheet flexibility

Material deleveraging and a substantial equity base increase financial flexibility for opportunistic M&A, capital return, and working-capital swings. Low net leverage reduces covenant risk and supports resilience during category or supply disruptions.

Negative Factors

Clear Eyes supply constraints

Persistent supply limitations for a flagship brand have driven durable revenue headwinds and inventory gaps. Recovery is multi-quarter and management expects restocking into fiscal 2027, meaning revenue growth and category share may be impaired until capacity fully normalizes.

Category demand weakness

Structural softness in core OTC categories reduces organic growth potential and raises reliance on a few stronger lines. Prolonged weak category volumes constrain topline recovery, limit pricing leverage, and increase the importance of new product and channel execution.

Earnings volatility and one-off charges

Historical profit volatility and recent write-offs highlight exposure to supply-chain and counterparty risks. Such episodic charges and uneven revenue trends complicate forecasting, capital allocation and investor confidence, making long-term earnings less predictable.

Prestige Consumer Healthcare Business Overview & Revenue Model

Company Description

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

How the Company Makes Money

Prestige Consumer Healthcare generates revenue primarily through the sale of its OTC healthcare products across various distribution channels, including retail, e-commerce, and pharmacy outlets. The company has a diverse range of revenue streams, with sales from both established brands and new product launches contributing significantly to its earnings. Key revenue streams include direct sales to retailers and wholesalers, as well as online sales through platforms like Amazon. Additionally, PBH engages in strategic partnerships with retailers, which can enhance brand visibility and accessibility, thereby driving sales. Seasonal demand, product innovation, and effective marketing strategies also play crucial roles in boosting the company's revenues.

Prestige Consumer Healthcare Financial Statement Overview

Summary

Strong and consistent cash generation (operating cash flow ~$230–$277M; high free-cash-flow-to-net-income conversion) and solid recent profitability (TTM gross margin ~56%, net margin ~17%) support the score. Offsetting factors are revenue growth uncertainty (very weak TTM revenue growth) and demonstrated earnings volatility (notably the 2023 loss year).

Income Statement

Profitability is solid in the most recent TTM (Trailing-Twelve-Months) period, with strong gross margin (~56%) and healthy operating profitability (EBIT margin ~21%, EBITDA margin ~30%) translating into a good net margin (~17%). Annual results in 2024 and 2025 show consistently high margins and net income around $209–$215M. The main concern is growth and volatility: TTM revenue shows a sharp decline (reported -61.9% growth rate), and earnings were severely disrupted in 2023 with negative operating profit and net losses, highlighting potential one-off impacts or sensitivity to disruptions.

Balance Sheet

Leverage has improved materially over time, with debt-to-equity declining from ~1.12 (2021) to ~0.57 (2025 annual) and very low in the latest TTM snapshot (~0.03), which meaningfully strengthens balance sheet flexibility. Equity remains substantial (~$1.83B) against total assets (~$3.49B TTM). Returns on equity are generally healthy in profitable years (~10–13%), but the 2023 loss year drove negative ROE, showing that profitability swings can quickly pressure shareholder returns.

Cash Flow

Cash generation is consistently strong: operating cash flow runs ~$230–$277M across periods, and free cash flow closely tracks net income (free cash flow to net income ~0.91–0.97), indicating good earnings quality and cash conversion. Free cash flow also appears resilient, with positive growth in 2024 and 2025 annual periods and a strong TTM (Trailing-Twelve-Months) free-cash-flow growth figure. A watch item is that free cash flow dipped in 2023 (negative growth), though it remained positive and coverage vs net income stayed robust.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.10B	1.14B	1.13B	1.13B	1.09B	943.37M
Gross Profit	622.30M	634.46M	624.45M	625.29M	620.65M	547.47M
EBITDA	338.53M	361.99M	373.86M	7.87M	358.84M	316.61M
Net Income	186.50M	214.60M	209.34M	-82.31M	205.38M	164.68M
Balance Sheet
Total Assets	3.49B	3.40B	3.32B	3.35B	3.67B	3.43B
Cash, Cash Equivalents and Short-Term Investments	62.37M	97.88M	46.47M	58.49M	27.18M	32.30M
Total Debt	1.08B	1.04B	1.14B	1.37B	1.51B	1.51B
Total Liabilities	1.67B	1.57B	1.66B	1.91B	2.09B	2.07B
Stockholders Equity	1.83B	1.83B	1.66B	1.45B	1.58B	1.36B
Cash Flow
Free Cash Flow	267.19M	243.29M	239.38M	221.93M	250.28M	213.36M
Operating Cash Flow	276.63M	251.51M	248.93M	229.72M	259.92M	235.61M
Investing Cash Flow	-136.91M	-17.45M	-20.11M	-11.58M	-256.51M	-22.24M
Financing Cash Flow	-129.45M	-182.07M	-241.01M	-185.85M	-7.57M	-279.42M

Prestige Consumer Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 69.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 69.07 is above the 20-day moving average (MA) of 67.77, above the 50-day MA of 65.48, and above the 200-day MA of 68.43, indicating a bullish trend. The MACD of 1.18 indicates Positive momentum. The RSI at 59.00 is Neutral, neither overbought nor oversold. The STOCH value of 54.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.

Prestige Consumer Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MCK	74 Outperform	$119.88B	21.30	―	0.37%	17.23%	66.17%
PBH	73 Outperform	$3.26B	15.81	11.29%	―	-0.02%	-1.87%
CAH	73 Outperform	$52.52B	25.74	―	0.98%	4.37%	28.48%
GRDN	70 Outperform	$2.16B	41.49	25.85%	―	18.68%	―
HSIC	65 Neutral	$9.20B	23.11	11.39%	―	3.51%	29.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Prestige Consumer Healthcare Corporate Events

Prestige Consumer Healthcare Reports Q3 Results, Narrows Outlook

On February 5, 2026, Prestige Consumer Healthcare reported that third-quarter fiscal 2026 revenue for the period ended December 31, 2025 declined 2.4% year-on-year to $283.4 million, as constrained supply of its Clear Eyes products weighed on its Eye & Ear Care category, pulling down both North American and international OTC segment sales. Net income for the quarter fell to $46.7 million, or $0.97 per diluted share, while adjusted diluted EPS came in at $1.14, reflecting adjustments related to a supplier loan write-off and acquisition-related costs. For the first nine months of fiscal 2026, revenue dropped 4.1% to $807.1 million and diluted EPS slid to $2.78, though free cash flow strengthened to $208.8 million, supporting $155.6 million of share repurchases and leaving net debt at about $1.0 billion with leverage of 2.6x. The company closed its acquisition of eye care supplier Pillar5 Pharma in December and, while acknowledging a challenging consumer environment and ongoing Clear Eyes supply issues, narrowed its full-year fiscal 2026 outlook to approximately $1.1 billion in revenue and about $4.54 in adjusted diluted EPS, while reaffirming free cash flow guidance of at least $245 million, underscoring continued emphasis on cash generation, brand-building and disciplined capital allocation.

The most recent analyst rating on (PBH) stock is a Hold with a $66.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.

Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results

On November 6, 2025, Prestige Consumer Healthcare reported its financial results for the second quarter and first half of fiscal 2026, ending September 30, 2025. The company achieved revenues of $274.1 million in Q2, slightly below the previous year’s $283.8 million due to supply constraints in the Eye & Ear Care category. Despite this, the company exceeded its sales and earnings expectations, driven by strategic brand-building and share repurchases. The fiscal 2026 revenue outlook remains unchanged, but the adjusted diluted EPS outlook has been updated to the higher end of the previous range. The company continues to focus on rebuilding supply chain capacity for Clear Eyes and anticipates improvements in the second half of the fiscal year.

The most recent analyst rating on (PBH) stock is a Hold with a $71.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.